10/01/2019 20:01:03

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Axogen, Inc.

NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces it has commenced an investigation of Axogen, Inc. (“Immunomedics” or “the Company”) (NASDAQ: AXGN) concerning possible violations of federal securities laws.

On December 18, 2018, Seligman Investments issued a report stating, among other things, that “[a] number of former [AxoGen] employees allege channel stuffing [at AxoGen], given that the company’s consignment model creates potential for abuse, as well as alleging questionable revenue recognition practices.” On  this  news,  the Company’s share price fell $6.17 per share, or nearly 22%, to close at $21.36 per share on December 18, 2018, on unusually high trading volume. To obtain additional information, go to:

https://www.zlk.com/pslra-1/axogen-inc-loss-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   

Levi & Korsinsky, LLP

Eduard Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

Tel: (212) 363-7500

Toll Free:  (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

250x148_zlk.jpg

Related content
23 May - 
Axogen, Inc. to Participate at Upcoming Investor Confer..
08 May - 
Axogen, Inc. Reports 2019 First Quarter Financial Resul..
02 May - 
Axogen, Inc. Appoints New Members to Board of Directors
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
5
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

Related stock quotes

AxoGen Inc 20.25 0.8% Stock price increasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 10:46:44
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB4 - 2019-06-16 11:46:44 - 2019-06-16 10:46:44 - 1000 - Website: OKAY